IMMUNEO Therapeutics Partners with Fraunhofer Institute to Advance BITAP and PAN-BITAP Peptide Research Using 3D Tumor Models

IMMUNEO Therapeutics announces a new collaboration with the Fraunhofer Institute to study the efficacy and pharmacology of its BITAP and PAN-BITAP peptides using advanced 3D tumor models.

IMMUNEO Therapeutics has partnered with the Fraunhofer Institute, University of Würzburg, to advance understanding of the pharmacology and efficacy of BITAP and PAN-BITAP peptides across multiple tumor types. This collaboration brings together expertise from Prof. Dr. Gudrun Dandekar’s team in tissue and tumor biology and IMMUNEO’s peptide-based immunotherapy programs.

The project leverages cutting-edge 3D tumor models, grown on biological tissue matrices and cultured dynamically in bioreactors, to replicate human tumor microenvironments. These models allow researchers to assess drug efficacy and safety in a physiologically relevant system, providing a promising alternative to animal testing.

This collaboration, initiated in March 2023, will combine experimental tissue models with in silico systems biology analysis, aiming to generate robust preclinical data on BITAP and PAN-BITAP peptides while adhering to modern ethical and regulatory standards.